These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review. Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319 [TBL] [Abstract][Full Text] [Related]
23. The Treatment of Activated PI3Kδ Syndrome. Coulter TI; Cant AJ Front Immunol; 2018; 9():2043. PubMed ID: 30245694 [TBL] [Abstract][Full Text] [Related]
24. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S Front Immunol; 2018; 9():543. PubMed ID: 29599784 [TBL] [Abstract][Full Text] [Related]
25. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome. Condliffe AM; Chandra A Front Immunol; 2018; 9():338. PubMed ID: 29556229 [TBL] [Abstract][Full Text] [Related]
26. Successful Sirolimus Treatment for Korean Patients with Activated Phosphoinositide 3-kinase δ Syndrome 1: the First Case Series in Korea. Kang JM; Kim SK; Kim D; Choi SR; Lim YJ; Kim SK; Park BK; Park WS; Kang ES; Ko YH; Choe YH; Lee JW; Kim YJ Yonsei Med J; 2020 Jun; 61(6):542-546. PubMed ID: 32469178 [TBL] [Abstract][Full Text] [Related]
28. Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD-the Goldilocks' Effect. Tangye SG; Bier J; Lau A; Nguyen T; Uzel G; Deenick EK J Clin Immunol; 2019 Feb; 39(2):148-158. PubMed ID: 30911953 [TBL] [Abstract][Full Text] [Related]
29. Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4 Bier J; Rao G; Payne K; Brigden H; French E; Pelham SJ; Lau A; Lenthall H; Edwards ESJ; Smart JM; Cole TS; Choo S; Joshi AY; Abraham RS; O'Sullivan M; Boztug K; Meyts I; Gray PE; Berglund LJ; Hsu P; Wong M; Holland SM; Notarangelo LD; Uzel G; Ma CS; Brink R; Tangye SG; Deenick EK J Allergy Clin Immunol; 2019 Jul; 144(1):236-253. PubMed ID: 30738173 [TBL] [Abstract][Full Text] [Related]
30. Exhaustion of the CD8 Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD Front Immunol; 2018; 9():446. PubMed ID: 29563914 [TBL] [Abstract][Full Text] [Related]
31. Herpesviruses in the Activated Phosphatidylinositol-3-Kinase-δ Syndrome. Cohen JI Front Immunol; 2018; 9():237. PubMed ID: 29599765 [TBL] [Abstract][Full Text] [Related]
32. [Activated phosphoinositide 3-kinase delta syndrome: report of seven cases]. Liu QH; Peng L; Huang H; Deng LJ; Zhong LL Zhongguo Dang Dai Er Ke Za Zhi; 2024 May; 26(5):499-505. PubMed ID: 38802911 [TBL] [Abstract][Full Text] [Related]
33. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment. Lougaris V; Piane FL; Cancrini C; Conti F; Tommasini A; Badolato R; Trizzino A; Zecca M; De Rosa A; Barzaghi F; Pignata C Ital J Pediatr; 2024 May; 50(1):103. PubMed ID: 38769568 [TBL] [Abstract][Full Text] [Related]
34. Exploring the Significance of Immune Checkpoints and EBV Reactivation in Antibody Deficiencies with Near-Normal Immunoglobulin Levels or Hyperimmunoglobulinemia. Mertowska P; Mertowski S; Smolak K; Pasiarski M; Smok-Kalwat J; Góźdź S; Grywalska E Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894426 [TBL] [Abstract][Full Text] [Related]
35. Could Immune Checkpoint Disorders and EBV Reactivation Be Connected in the Development of Hematological Malignancies in Immunodeficient Patients? Mertowska P; Mertowski S; Smolak K; Kita G; Guz K; Kita A; Pasiarski M; Smok-Kalwat J; Góźdź S; Grywalska E Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835480 [TBL] [Abstract][Full Text] [Related]
36. PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond. Cant AJ; Chandra A; Munro E; Rao VK; Lucas CL J Allergy Clin Immunol Pract; 2024 Jan; 12(1):69-78. PubMed ID: 37777067 [TBL] [Abstract][Full Text] [Related]
37. Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation. Toskov V; Ehl S Mol Cell Pediatr; 2023 Sep; 10(1):11. PubMed ID: 37702894 [TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus-associated B-cell lymphoproliferative disorder meeting the definition of CAEBV B cell disease: a case report. Ma Y; Bao Y; Zheng M BMC Infect Dis; 2023 Jul; 23(1):453. PubMed ID: 37420238 [TBL] [Abstract][Full Text] [Related]